Toxic hepatitis secondary to oral administration of exemestane
Tóm tắt
Từ khóa
Tài liệu tham khảo
Di Salle E, Giudici D, Briatico G, et al. Novel irreversible aromatase inhibition. Ann NY Acad Sci 1990;599:357–67.
Di Salle E, Giudici D, Briatico G. et al. Novel aromatase and 5 alpha-reductase inhibitors. J Steroid Biochem Mol Biol 1994;49:280–94.
Crucitta E, Fornier MN, Locopo N, et al. Current status and future potential role of exemestane in the treatment of early and advanced breast cancer [review]. Int J Oncol 2002;20(6):1283–8.
Kaufman M, Bajjeta E, Dirix LY, et al. Exemestane is superior to megestrol acetate following tamoxifen failure in post-menopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. J Clin Oncol 2000;18:1399–411.
Aromasil (exemestane tablets) summary of product characteristics, Pharmacia & Upjohn Limited, Milton Keynes, United Kindom.
Jones S, Belt R, Cooper B. A phase II study of antitumor efficacy and safety of exemestane (EXE) as second-line hormonal treatment of postmenopausal patients with metastatic breast cancer (MBC) refractory to tamoxifen (Tam) [abstract 436]. Breast Cancer Res Treat 1998;50:304.
Kvinnsland S, Anker G, Dirix LY, et al. High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment. Eur J Cancer 2000;36(8):976–82.
Lonning PE, Bajjeta E, Murray R, et al. Phase II study of exemestane (EXE) in metastatic breast cancer (MBC) patients failing non-steroidal aromatase inhibitors (ns-Als) [abstract 435]. Breast Cancer Res Treat 1998;50:304.
Jones C, Vogel L, Frebenbacher P. Antitumor efficacy of exemestane (Nikidens, EXR) as third-line hormonal therapy in the treatment of postmenopausal women with metastatic breast cancer refractory to tamoxifen and megestrol acetate [abstract 573]. Proc Am Soc Clin Oncol 1998;17:150.